Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 13, 2007Arteriosclerosis Thrombosis and Vascular Biology

Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants

View Full Paper
Ask AI
Bookmark
Share

Key result

APOA5 56G carriers exhibited a significantly greater reduction in fasting triglycerides (-35.8% vs -27.9%, P=0.006) and increase in HDL-C after 3 weeks of fenofibrate treatment compared to noncarriers.

Why the study?

Does the response to fenofibrate therapy differ based on APOA5 genetic variants in men and women?

Population

791 men and women participating in the GOLDN study

Comparison

Fenofibrate therapy for 3 weeks and a… vs Noncarriers of the APOA5 56G variant

Design

Cohort

Follow-up

3 weeks

Authors

CLChao‐Qiang LaiDADonna K. ArnettDCDolores Corella

Discussion

Loading...

Member takes

Overview

APOA5 56G was associated with enhanced fenofibrate response; hypothesis-generating and should not yet change practice.

Key Points

  • This research investigates how genetic variations in apolipoprotein A5 affect triglyceride response to fenofibrate treatment.
  • Examined association between tag SNPs at APOA5 and triglyceride, HDL-C response to fenofibrate.
  • Involved 791 participants from the GOLDN study over a 3-week drug treatment.
  • Analyzed postprandial lipid responses after fat load.
  • APOA5 56G carriers showed a significant TG reduction of -35.8% (P=0.006) and HDL-C increase of 11.8% (P=0.002).
  • Noncarriers had a TG reduction of -27.9% and HDL-C increase of 6.9%.
  • 56G carriers demonstrated a reduced postprandial TG area under the curve compared to noncarriers.

Study Design

Type

Cohort (n=791)

Structured PICO

Does the response to fenofibrate therapy differ based on APOA5 genetic variants in men and women?

P
Population
791 men and women participating in the GOLDN study, evaluated for lipid response to a 3-week fenofibrate treatment and postprandial fat challenge.
E
Exposure
Fenofibrate therapy for 3 weeks and a postprandial lipid challenge
C
Comparator
Noncarriers of the APOA5 56G variant
O
Outcome
Triglyceride (TG) and HDL-C response to fenofibrate and a postprandial lipid challengesurrogate

Main Result

Absolute Event Rate: -35.8% vs -27.9%

p-value: p=0.006

Carriers of the APOA5 56G variant derive significantly greater triglyceride-lowering and HDL-raising benefits from fenofibrate therapy compared to noncarriers.

Cite This Study

Lai et al. (2007) reported a cohort. APOA5 56G carrier status vs. APOA5 56G noncarriers was evaluated on Triglyceride reduction (p=0.006). APOA5 56G carriers exhibited a significantly greater reduction in fasting triglycerides (-35.8% vs -27.9%, P=0.006) and increase in HDL-C after 3 weeks of fenofibrate treatment compared to noncarriers.

synapsesocial.com/papers/6a5d96f11736c081110366bchttps://doi.org/10.1161/atvbaha.107.140103
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.2002 · 74 citations
  2. 2Give me A5 for lipoprotein hydrolysis!2005 · 93 citations
  3. 3Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism1998 · 1,800 citations
  4. 4Atherogenesis: a postprandial phenomenon.1979 · 1,714 citations
  5. 5New Risk Factors for Atherosclerosis and Patient Risk Assessment2004 · 351 citations